This study is in progress, not accepting new patients
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
a study on Breast Cancer
Breast Cancer BYL719 HR+ HER2-negative advanced breast cancer alpelisib fulvestrant PI3K Phase III ER+ PgR+ men postmenopausal aromatase inhibitor neoplasms Breast Neoplasms Aromatase Inhibitors fulvestrant + alpelisib
Lead Scientist at UCSF
- Michelle Melisko
Dr. Michelle E. Melisko is a cancer specialist with expertise in breast cancer treatment and research. She is interested in testing new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treatment of cancer that has spread to the brain.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Novartis Pharmaceuticals
- Phase 3
- Study Type
- Last Updated